Title
Distinguishing the four genetic causes of Joubert's syndrome-related disorders

Permalink
https://escholarship.org/uc/item/8mg3966w

Journal
Annals of Neurology, 57(4)

ISSN
0364-5134

Authors
Valente, E M
Marsh, S E
Castori, M
et al.

Publication Date
2005-04-01

Peer reviewed
Mutations in the *CEP290* gene, encoding a centrosomal protein, cause pleiotropic forms of Joubert Syndrome

Enza Maria Valente,1* Jennifer L. Silhavy,2* Francesco Brancati,1,3 Giuseppe Barrano,1,4 Suguna Rani Krishnaswami,2 Marco Castori,1,4 Madeline A. Lancaster, 2 Eugen Boltshauser,5 Loredana Boccone,6 Lihadh Al-Gazali,7 Elisa Fazzi,8 Sabrina Signorini,8 Carrie M. Louie, 2 Emanuele Bellacchio,1 the International JSRD Study Group, Enrico Bertini,9 Bruno Dallapiccola,1,4 Joseph G. Gleeson.2

1IRCCS CSS, Mendel Institute, viale Regina Margherita 261, 00198 Rome, Italy, tel. +39 (06) 4416 0503
2Laboratory of Neurogenetics, Department of Neurosciences, University of California, San Diego, Leichtag 332, 9500 Gilman Drive, La Jolla, CA 92093-0691, USA, tel. +1 (858) 822 3535
3Department of Biological Sciences, G. D'Annunzio University, Via dei Vestini 31, 66013 Chieti, Italy, tel. +39 (0871) 3554137
4Department of Experimental Medicine and Pathology, La Sapienza University, viale Regina Elena 324, 00187 Rome, Italy, tel. +39 (06) 4416 0501
5Department of Neurology, Children's University Hospital, Steinwiesstrasse 75, 8032 Zurich, Switzerland, tel. +41 (1) 266 7330
6Ospedale Microcitemico, Cagliari, Italy, tel. +39 (070) 6095666
7Department of Pediatrics, Faculty of Medicine and Health Sciences, United Emirates University, PO Box 17666, Al Ain, United Arab Emirates, tel. +971 (3) 703 9415 and +971 (3) 767 2022
8Department of Child Neurology and Psychiatry, IRCCS "C. Mondino Foundation", University of Pavia, Italy, tel. +39 (0382) 380 280
9Molecular Medicine Unit, Department of Laboratory Medicine, Bambino Gesu' Hospital IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy, tel. +39 (06) 6859 2105

*these two authors contributed equally to this work.

**Corresponding author:**
Joseph G. Gleeson
University of California-San Diego
Leichtag 332
9500 Gilman Drive
La Jolla, CA 92093-0624
tel. +1 (858) 822 3535
fax. +1 (858) 822 1021
e-mail: jogleeson@ucsd.edu
**Introductory paragraph**

Joubert syndrome is a severe developmental disorder mainly consisting of ataxia, oculomotor apraxia and mental retardation and characterized by cerebellar vermis hypoplasia and a peculiar brainstem malformation known as the “molar tooth sign”\(^1,2\). Patients frequently display additional features of cystic kidney disease progressing to renal failure and ocular manifestations including retinopathy, encompassing the Joubert Syndrome Related Disorders (JSRD) group of conditions\(^3-5\). We used homozygosity mapping to identify a novel locus on chromosome 12 and subsequently truncating mutations in the *centrosomal protein 290* (*CEP290*) gene in four families and a missense mutation in a fifth family. These families display pleiotropic forms of JSRD with variable retinal and renal manifestations. *CEP290* expression was detected in developing murine tissues, most notably in proliferating cerebellar granule neuron populations, and showed centrosome and cilia intracellular localization in non-neuronal cells. Our data imply a direct connection between JSRDs and other cilia/centrosomal human disorders such as isolated nephronophthisis, Senior-Loken, Bardet-Biedl and Meckel syndromes\(^6,7\).
Joubert syndrome (JS) is an autosomal recessive disorder presenting with psychomotor delay, hypotonia, ataxia, oculomotor apraxia and breathing abnormalities in the neonatal period. Neuroradiologically, JS is characterized by a peculiar malformation of the midbrain-hindbrain junction known as the “molar tooth sign” (MTS), consisting of cerebellar vermis hypo/aplasia, thick and mal-oriented superior cerebellar peduncles and abnormally deep interpeduncular fossa. The MTS has subsequently been reported in a group of syndromes termed “Joubert Syndrome Related Disorders” (JSRDs), displaying the neurological features of JS associated with involvement of other organs such as the eye and kidney (mainly retinal dystrophy and nephronophthisis). Additional clinical features include optic coloboma, polydactyly, liver fibrosis and other central nervous system malformations. At least eight distinct syndromes sharing the MTS have been described so far. However, their nosologic delineation is still problematic due to the wide phenotypic variability both within and among families. Genetic heterogeneity mirrors clinical heterogeneity of JSRDs, with two genes (AHI1/JBTS3 and NPHP1/JBTS4) and two additional genetic loci (JBTS1 and JBTS2) identified so far. Mutations in the AHI1 gene (chromosome 6q23, MIM[608894]) account for about 10% of patients with the MTS and lead to a prevalent phenotype of JS plus retinal abnormalities, with the kidneys usually spared. Homozygous deletions of NPHP1 (chromosome 2q13, MIM[607100]), which represent the most frequent cause of juvenile isolated nephronophthisis, have been described only in four JSRD patients with invariable renal involvement and occasional retinopathy. To date, four families with pure cerebellar phenotype are linked to JBTS1 (chromosome 9q34, MIM[213300]) while linkage to JBTS2 (chromosome 11p12-q13, MIM[608091]) has been detected in six families characterized by multiorgan involvement and
striking phenotypic variability\textsuperscript{18}. In our series, eighteen consanguineous JSRD families did not show linkage to any of the known loci, supporting further genetic heterogeneity. In the largest family (COR27), a simulation study performed with the program SLINK revealed a maximum expected LOD score of 3.60, indicating that this family was informative to detect linkage. A 10-cM resolution genome-wide screen identified a marker on chromosome 12q (D12S1064) that generated a LOD score of 3.46 in family COR27 and positive LOD scores in additional seven smaller families. The region surrounding this marker was saturated with densely spaced microsatellite markers and haplotypes were constructed. A combination of negative LOD scores and the presence of heterozygous genotypes in affected individuals allowed exclusion of linkage in two small families. Conversely, all affected individuals in the remaining six families shared a 2.7 cM region of homozygosity by descent between markers D12S1670 and D12S351, identifying a novel locus which we termed JBTS5 (Fig. 1). Pooled LOD scores for the six pedigrees resulted in a maximum cumulated two point LOD score of 8.54 for marker D12S1064 at recombination fraction = 0 (Supplementary Table 1). The JBTS5 region spans 8.4 Mb on the physical map of chromosome 12 and contains 21 genes (Fig. 2a). The \textit{CEP290} gene, encoding a putative 2480 aa centrosomal protein, was selected as a good candidate because of the key role played by centrosomal and ciliary proteins in several disorders showing overlapping features with JSRDs, such as cystic kidney diseases, Bardet-Biedl and Meckel syndromes\textsuperscript{6,7} (Fig. 2b). We identified independent homozygous nucleotide changes in \textit{CEP290} in five of the six linked families. Three of these (4732G>T, 5668G>T and 5824C>T) were nonsense mutations resulting in premature truncation of the protein (E1578X, G1890X and Q1942X), and were detected in families from Italy (COR27), Turkey (COR51) and Palestine (MTI133). In family MK05 from Turkey,
we identified a 1 bp deletion in exon 28 (3176delT) resulting in a frameshift and generation of a premature stop codon (I1059fsX1064). The fifth mutation (21G>T), identified in Pakistani family COR22, resulted in a nonconservative W7C substitution that affected a highly conserved residue of the protein (Fig. 2c).

All mutations segregated with the disease and were not detected in 300 control chromosomes of Italian and Asian origin. In the remaining family consistent for linkage to JBTS5 (MK20), no coding mutations have been identified to date. Either this family harbors mutations in non-coding regions of CEP290 or, alternatively, the disease is due to mutations in a distinct, as yet unidentified, gene.

The phenotype associated with CEP290 mutations is mainly characterized by the neurological features of JS associated with severe retinal and renal involvement. However the clinical spectrum is broad, including incomplete phenotypes such as cerebello-retinal and cerebello-renal syndromes. Additional features are rare, with one patient with cleft palate and another one with possible liver involvement (Table 1 and Fig. 3). The full-blown JBTS5 phenotype overlaps with Senior-Loken syndrome (SLS), characterized by retinitis pigmentosa plus juvenile nephronophthisis and occasionally associated with neurological involvement and the MTS4,5. Mutations in most nephronophthisis-related genes, encoding ciliary proteins, have been shown to cause SLS, but neurological and neuroradiological features typical of JS were never reported in these patients19-22.

We tested the temporal and regional expression of Cep290 using both RT-PCR and in situ hybridization in mouse brain. A full-length murine Cep290 was assembled from three partially-overlapping cDNA contigs from the human genome browser. The construct encodes a predicted protein that is 89% identical to the full-length human protein on a region syntenic with the human chromosome 12 interval. Northern blot
analysis of whole mouse embryo showed roughly equal expression at embryonic day (E) 7-17 (Fig. 4a). We found approximately equal expression levels of the Cep290 mRNA in various regions from mouse brain across developmental timepoints using RT-PCR (embryonic day 7 through postnatal day 17), suggesting a possible role for this protein in embryogenesis of several brain structures (data not shown). Cep290 was expressed in multiple organs tested during early postnatal development (P0), with two major transcripts present on Northern blot analysis. Bands of approximately 4.6 and 7.9 kb were detected in roughly equal relative ratios, with the highest levels of expression in the hindbrain, and lower levels in other organs (Fig. 4b). The 4.6 kb transcript likely corresponds to cDNA clone AK172940, however no 5’ stop codon was detected in this clone. The 7.9 kb transcript corresponds to the full length human and mouse Cep290 predicted mRNAs. In situ hybridization analysis of the cerebellum using a ubiquitous cDNA fragment showed the strongest expression in dividing cell populations of the external granule layer (EGL) during development, suggesting a possible role for Cep290 in cell division. The gene was also expressed in the internal granule layer cell population (which derive from the EGL through cell migration) in both development and adulthood (Fig. 4c). Regions of the telencephalon containing dividing cells also expressed relatively higher levels of Cep290 (data not shown).

Intracellular localization of mouse CEP290 fused to EGFP was examined in both non-ciliated and ciliated cells. A plasmid encoding the constitutive centrosomal protein Centrin 2 fused to DSRedII (CETN2-RFP), which labels the pair of centrioles, was used to stably transfect 293T human non-ciliated kidney cells. These cells were chosen due to the kidney phenotype observed in our patients. GFP-CEP290 localized to the region surrounding the centrioles (i.e. the pericentriolar matrix) in all
transfected cells (Fig. 5a), consistent with the putative centrosomal localization. To
test for ciliary localization, we next utilized murine kidney intramedullary collecting
duct (IMCD-3) kidney cells that are able to form cilia when grown at confluence.
GFP-CEP290 was found to localize to the base of the cilia, as defined by staining for
the pericentriolar matrix protein pericentrin and the stabilized microtubule marker
acetylated tubulin (Fig. 5b-c). A plasmid encoding GFP-CEP290 with the W7C
mutation showed localization that was not significantly different from wildtype GFP-
CEP290 (data not shown).
The CEP290 product encodes a large protein with a nearly uninterrupted series of
coiled-coil domains. The protein has been first identified as 3H11Ag, a tumour-
associated antigen defined by the monoclonal antibody 3H11 that specifically
recognizes cancer cells in various neoplastic tissues. The cDNA encoding the protein
was subsequently cloned from a gastric cancer cell line and the gene mapped to
chromosome 12q23. Although the protein function was unknown, Northern blot and
RT-PCR experiments showed that 3H11Ag mRNA was extensively distributed in
embryonic tissue and in different cancerous tissues, but not in corresponding adult
tissues, thus suggesting a role for the underlying protein in embryonic development23.
Subsequently, 3H11Ag was identified as a centrosomal protein through a mass-
spectrometry based proteomic approach, and named CEP29024. Centrosomes are
the major microtubule-organizing centers of animal cells. They are involved in the
control of ciliary activity and in regulation of cell shape, polarity, motility and cell
division through effects on the mitotic spindle25,26.
An increasing number of disorders associated with cystic kidney disease have been
linked to mutations in proteins expressed in cilia or centrosomes7. These proteins
share multiple coiled-coil, SH3 and WD40 modular protein-protein interaction
domains. Such proteins may form multimeric complexes in centrosomes and cilia of different tissues, including renal epithelial cells, retinal photoreceptors, cholangiocytes of the bile duct and neuronal axons. Interestingly, the AHI1 gene product also contains several interaction domains, although its subcellular localization to cilia or centrosomal structures has not been tested. These findings provide a unifying frame to understand the pathogenetic mechanism of both isolated renal cystic disorders and distinct pleiotropic syndromes characterized by multiorgan involvement, including JSRDs. Ciliary and centrosomal proteins may interact to respond to extracellular signaling or modulatory cues that are key in maintenance of kidney and retinal homeostasis, and in neuronal development. In particular, defective intraciliary and axonal transport could cause impaired axonal outgrowth possibly responsible for the malformations of the cerebellum and brainstem observed in JSRDs. The identification of CEP290 mutations in patients without renal involvement broadens the phenotypic spectrum associated with disorders of ciliary and centrosomal proteins, and may facilitate the identification of other JSRD genes.

Methods

Patients and families. Eighteen consanguineous families from Europe, the Middle East, Asia and North America were selected on the basis of the following criteria: 1) at least one individual with a neuroradiologically proven MTS associated with any JSRD phenotype; 2) exclusion of linkage to known JBTS loci (JBTS1 to 4). Whenever possible, patients underwent a full diagnostic protocol as previously reported. Parental written informed consent was obtained from all families and the study was approved by the Ethics Committees of UCSD (La Jolla) and CSS-Mendel Institute (Rome).

Genome-wide screen and fine mapping of the JBTS5 locus. The genome-wide
screen was performed in 75 individuals including 26 patients and 49 unaffected first degree relatives, by genotyping 402 microsatellite markers (Marshfield Screening Set 13) with an average inter-marker distance of 10cM. Two-point LOD scores were generated using the FASTLINK version of the MLINK program, assuming equal male-female recombination rate, autosomal recessive inheritance, a gene frequency of 0.001 with complete penetrance and equal allele frequencies for each marker. To saturate the 8.4 Mb region surrounding marker D12S1064, additional markers were selected from the May 2004 UCSC draft of the Human Genome. As no informative markers were available in a 5.2 Mb interval within the locus, we generated two novel microsatellite markers using the Tandem Repeat Finder software, as previously reported. Details of these new markers are in Supplementary Table 2. Genomic DNA was PCR-amplified using fluorescent primers. Amplified fragments were run on an ABI Prism 3100 DNA sequencer and analyzed with GeneScan and Genotyper software (Applied Biosystems). Haplotypes were manually constructed, and phase was assigned based on the minimum number of recombinants.

Mutation analysis. PCR primers to amplify CEP290 53 coding exons and exon-intron boundaries were manually designed on the chromosome 12 draft of the human genome (Supplementary Table 3). Sequencing analysis was carried out using the dideoxy chain termination method (BigDye 3.0) on an ABI 3100 DNA automated sequencer according to standard procedures and the manufacturer’s recommendations (Applied Biosystems). Sequences of affected individuals were analyzed and compared to those of controls by using the SeqMan software (DNASTAR Inc.). Identified mutations were confirmed at least twice by bidirectional sequencing.

Gene expression analysis with quantitative RT-PCR. We purified total RNA from
whole brain, cerebellum and cortex of mice (E14, E16, E18, P5, P10 and adult) using a standard Trizol method (Invitrogen). cDNA was reverse-transcribed from total RNA (5 µg) using SuperScript™ III First-Strand Synthesis System (Invitrogen) with oligo(dT) primers. We PCR-amplified a ubiquitous fragment at 3' of Cep290 ORF (primer forward: 5’-GAGACCAAGATGAAAGAGCTTGA-3’; reverse: 5’-GCTTTTTAACTTCTCTCTCG-3’) and GAPDH as an internal control. Each reaction was run in triplicate, and a negative control without cDNA template was run with each assay. Band intensities were quantified by ImageQuant v1.1 (Molecular Dynamics) and band intensities for Cep290 were standardized with Gapdh internal controls.

**Mouse in situ hybridization.** *In situ* hybridization on frozen mouse brain sections was performed using a non-radioactively digoxigenin-labeled cDNA probe. The Cep290 probe was amplified from mouse embryonic day 18 (E18) with primers specific to the three longest Cep290 mRNA transcripts (forward 5’-GAATGCTCTAGCCCAAGCAC-3’; reverse 5’-GTGGGCTTCTCCTTCCTTCT-3’). The 739bp probe was cloned into pCR-Blunt II-TOPO vector containing SP6 and T7 promoter priming sites. Antisense cDNA probe transcription was driven from the T7 promoter and transcription of the sense cDNA probe driven from the SP6 promoter. Mouse brain sections from embryonic through adult timepoints were fixed, and then hybridized using the digoxigenin-labeled cDNA probes overnight at 65°C. Sections were washed, treated with RNAase and washed again before being treated with antidigoxigenin coupled to alkaline phosphatase (Roche). After a further wash in 5M NaCl, 1M Tris base, 1M Tris-Hcl, 2M MgCl2 and 10% Tween-20, the digoxigenin-labeled cDNA probe was detected using NBT and BCIP and sections were stained overnight at room temperature.

**Northern-blot analysis.** We used the same Cep290 mouse genome sequence to
generate the *in situ* probe for the Northern Blot analysis. The probe was labelled with [α-32P]dCTP using the Prime-It II Random Primer Labeling Kit (Stratagene). A Clontech polyA-selected commercial blot was used to interrogate whole body expression. For specific organ analysis, total RNA was isolated from post-natal day 0 multiple mouse tissues using Trizol and tested for *Cep290* expression. After probe hybridization, the blots were developed according to the ExpressHyb Hybridization protocol (Clontech).

**Fluorescence microscopy.** The full length mouse *Cep290* (Accession XM_618806) was amplified with forward 5'-ATGCCACCTAATATAAAGTGGAAAGA-3' and reverse 5'-ATAAACACAGAGACTGCTTGATTTCC–3’ primers using Platinum® High Fidelity Taq DNA Polymerase (Invitrogen) and cloned into pCR®-XL-TOPO (Invitrogen) in reverse orientation. It was then sub-cloned into *Xho* and *Bam*HI sites of mammalian expression vector  pEGFP-C3 (Clontech). The patient missense mutation was introduced by site directed mutagenesis. The open reading frame of each clone was fully sequenced before use. 293T cells were transfected with RFP-CETN2 and stable cell lines were established. These were subsequently transfected with GFP-CEP290 and imaged 2 days later. IMCD-3 (ATTC) cells were transfected at 80% confluence, allowed to grow to confluence and develop cilia, then fixed and stained with antibodies to acetylated α-tubulin (Zymed), pericentrin (PRB-432, Covance), and centrin 2 (hCetn2.4 ascites, gift from J. Salisbury, Mayo). Images were captured on a DeltaVision deconvolution microscope and processed with Softworks software.

**Accession numbers.** GenBank: human *CEP290* mRNA, NM_025114; the full-length mouse mRNA, XM_618806 has been removed from the database and is constituted by the following cDNAs: AK172940, BI733169, CO043781, BE571692, and CB181153 with a small gap in the 5’ part of the ORF. GenBank protein: human full-length *CEP290* protein isoform, NP_079390.

**Acknowledgements**

We thank the Marshfield Clinic Research Foundation and NHBLI for genotyping support. We also thank Dr Carla Uggetti (UO Pediatric Neuroradiology, IRCCS "C. Mondino Foundation", University of Pavia) for her valuable contribution in reviewing MRIs of selected patients. We received help with imaging from Brendan Brinkman and the UCSD Neuroscience Microscopy Core and help with *in situ* hybridization from Wendy Books in the Hamilton lab. This work was supported by grants from the U.S. National Institute of Neurological Disease and Stroke, the Italian Ministry of Health (Ricerca Corrente 2006; Ricerca Finalizzata 2005 Progetto Malattie Rare Conv. 526/A36), the Fondazione Pierfranco e Luisa Mariani ONLUS, the March of Dimes, the Simons Foundation and the Burroughs Wellcome Fund Award in Translational Research.
References


Appendix

Other members of the International JSRD Study Group are as follows:

Richard Leventer (Parkville, Australia); Padraic Grattan-Smith (Sydney, Australia);
Andreas Janecke (Innsbruck, Austria); Marc D’Hooghe (Brugge, Belgium); Rudy Van
Coster (Ghent, Belgium); Karin Dias, Carla Moco, Ana Moreira (Porto Alegre, Brazil);
Chong Ae Kim (Sao Paulo, Brazil); Gustavo Maegawa (Toronto, Canada); Ghada
M.H. Abdel-Salam, Alice Abdel-Aleem, Maha S. Zaki (Cairo, Egypt); Itxaso Marti,
Susana Quijano-Roy (Garches, France); Pascale de Lonlay, Stéphane Romano,
Alain Verloes (Paris, France); Renaud Touraine (St. Etienne, France); Michel Koenig,
Clotilde Lagier-Tourenne, Jean Messer (Strasbourg, France); Heike Philippi (Mainz,
Germany); Sofia Kitsiou Tzeli (Athens, Greece); Saever Halldorsson (Reykjavik,
Iceland); Shubha R. Phadke (Lucknow, India); Bernard Stuart (Dublin, Ireland); Alex
Magee (Belfast, Northern Ireland); Dorit Lev (Holon, Israel); Bruria Ben-Zeev (Ramat-
Gan, Israel); Rita Fischetto, Mattia Gentile (Bari, Italy); Silvia Battaglia, Lucio
Giordano (Brescia, Italy); Martino Ruggieri (Catania, Italy); Stefania Bigoni,
Alessandra Ferlini (Ferrara, Italy); Maria Alice Donati, Elena Procopio (Florence,
Italy); Gianluca Caridi, Francesca Faravelli, Gianmarco Ghiggeri (Genoa, Italy);
Silvana Briuglia, Carmelo D. Salpietro, Gaetano Tortorella (Messina, Italy); Stefano
D’Arrigo, Chiara Pantaleoni, Daria Riva, Graziella Uziel (Milan, Italy); Anna Maria
Laverda, Alberto Permunian (Padova, Italy); Stefania Bova (Pavia, Italy); Roberta
Battini (Pisa, Italy); Maria Roberta Cilio, Marilù Di Sabato, Francesco Emma,
Vincenzo Leuzzi, Pasquale Parisi (Rome, Italy); Alessandro Simonati (Verona, Italy);
Mirjam M. de Jong (Groningen, The Netherlands); Matloob Azam (Islamabad,
Pakistan); Berta Rodriguez (La Coruna, Spain); Ignacio Pascual-Castroviejo (Madrid,
Spain); Hulya Kayserili (Istanbul, Turkey); Lihadh Al Gazali, Laszlo Sztriha (Al Ain,
UAE); David Nicholl (Birmingham, UK); C. Geoffrey Woods (Cambridge, UK); Raoul Hennekam (Oxford, UK); Sauner Bernes (Mesa, Arizona, US); Henry Sanchez (Fremont, California, US); Aldon E. Clark (Laguna Niguel, California, US); Elysa DeMarco, Clement Donahue, Elliot Sherr (San Francisco, California, US); Jin Hahn, Terence D. Sanger (Stanford California, US); Tomas E. Gallager (Manoa, Hawaii, US); William B. Dobyns (Chicago, Illinois, US); Cynthia Daugherty (Bangor, Maine, US); Kalpathy S. Krishnamoorthy, Dean Sarco, Christopher A. Walsh (Boston, Massachusetts, US); Trudy McKanna (Grand Rapids, Michigan, US); Joanne Milisa (Albuquerque, New Mexico, US); Wendy K. Chung, Darryl C. De Vivo, Hillary Raynes, Romaine Schubert (New York, New York, US); Alison Seward (Columbus, Ohio, US); David G. Brooks (Philadelphia, Pennsylvania, US); Amy Goldstein (Pittsburg, Pennsylvania, US); James Caldwell, Eco Finsecke (Tulsa, Oklahoma, US); Kenton Holden (Mt. Pleasant, South Carolina, US); Robert P. Cruse (Houston, Texas, US); Kathryn J. Swoboda, Dave Viskochil (Salt Lake City, Utah, US).
Figure legends

Figure 1
Pedigrees of JBTS5 linked families and haplotypes spanning the linked region. All affected individuals shared a 2.7 cM region of homozygosity between markers D12S1670 and D12S351 (dashed lines). In each family, a black bar denotes markers of the disease haplotype which are homozygous by descent in affected members, while the remaining markers of the same haplotype are represented as a white bar. Thin vertical lines interrupting the bars denote recombination events to the non-disease parental chromosome. Horizontal lines above symbols denote individuals who were clinically examined. Deceased individuals are marked by a diagonal line across symbols.

Figure 2
Identification of the *CEP290* gene within the JBTS5 region. a) Genetic map of the JBTS5 locus and detailed physical map showing the location of genetic flanking markers and genes of the region. Arrows indicate the transcriptional direction of each gene. *CEP290* is highlighted in blue. b) The 54 exons and the exon-intron structure of the *CEP290* gene are represented as vertical bars. The start (ATG) and stop (TAA) codons are indicated. c) Electropherograms of mutations found in five probands (upper panels) and healthy controls (lower panels).

Figure 3
Magnetic Resonance Imaging of probands with *CEP290* mutations. a,c,e,g,i (upper panel) and j (lower panel): axial sections at the pontine or ponto-mesencephalic level demonstrating the molar tooth sign (arrows); b,d,f,h (lower panel): paramedian
sagittal sections, showing the thickening and malorientation of superior cerebellar peduncles (arrows) and cerebellar vermis hypoplasia (arrowheads). For family COR51, sagittal sections were not available but axial sections of both affected siblings are presented (i: patient II:1 and j: patient II:2).

**Figure 4**

Expression pattern of *Cep290* in mouse. a) Northern blot from whole mouse embryo at specific embryonic (E) days show a 4.6 kb band. b) mouse tissues at postnatal day 0 showing bands at approximately 7.9 and 4.6 kb, with relatively higher expression in hindbrain compared with other regions. Bottom shows the same blots probed for G3PDH for loading control. c) *In situ* hybridization from embryonic (E) or postnatal (P) mouse cerebellum. Expression was noted in the external (arrowhead) and internal (arrow) granule layer (EGL and IGL) in the midline prior to foliation. Asterisk is choroid. At older ages during and after foliation, expression persists in this cell population. Scale bar = 200 μm.

**Figure 5**

Cep290 localizes to the centrosome and cilia in kidney cells. a) Human 293T cells. The arrow shows co-distribution of GFP-CEP290 (green) with the constitutive centrosomal marker RFP-CETN2. b-c) Intramedullary collecting duct (IMCD-3) murine kidney ciliated cells. Arrows show co-localization of GFP-CEP290 (green) with the pericentriolar matrix protein pericentrin (red, panel b), and with the base of the cilia (panel c). Arrowhead in panel (c) indicates the cilium marked by acetylated tubulin staining (red). In all panels, nuclei are stained blue with Hoechst. Scale bar = 5 μm.
### Table 1

Clinical findings of patients with *CEP290* homozygous mutations

<table>
<thead>
<tr>
<th>Family</th>
<th>COR27</th>
<th>COR51</th>
<th>MTI-133</th>
<th>COR22</th>
<th>MK05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of origin</td>
<td>Sardinia (Italy)</td>
<td>Turkey</td>
<td>Palestine</td>
<td>Pakistan</td>
<td>Turkey</td>
</tr>
<tr>
<td>Nucleotide change (exon)</td>
<td>4732G&gt;T (36)</td>
<td>5668G&gt;T (41)</td>
<td>5824C&gt;T (42)</td>
<td>21G&gt;T (2)</td>
<td>3176delT (28)</td>
</tr>
<tr>
<td>Protein mutation:</td>
<td>E157X</td>
<td>G1890X</td>
<td>Q1942X</td>
<td>W7C</td>
<td>I1059fsX1064</td>
</tr>
<tr>
<td>patient (sex)</td>
<td>V:1 (F)</td>
<td>V:2 (F)</td>
<td>V:4 (F)</td>
<td>II:1 (M)</td>
<td>II:2 (M)</td>
</tr>
<tr>
<td>Age at examination</td>
<td>15 yrs</td>
<td>3 yrs</td>
<td>10 yrs</td>
<td>17 yrs</td>
<td>15 yrs</td>
</tr>
<tr>
<td>Neurological signs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- hypotonia/ataxia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- psychomotor delay</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- mental retardation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- OMA</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- breathing abnormalities</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>- other abnormalities</td>
<td>ny</td>
<td>ny</td>
<td>ny, ptosis</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ocular signs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- retinopathy</td>
<td>CB</td>
<td>CB</td>
<td>CB</td>
<td>RP, vr</td>
<td>RP, vr</td>
</tr>
<tr>
<td>- other abnormalities</td>
<td>–</td>
<td>–</td>
<td>micropt LE</td>
<td>–</td>
<td>drusen in LE</td>
</tr>
<tr>
<td>Renal signs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- NPH/UCD</td>
<td>–</td>
<td>n.a.</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- kidney ultrasound</td>
<td>normal</td>
<td>normal</td>
<td>normal</td>
<td>n.a.</td>
<td>CC</td>
</tr>
<tr>
<td>Other organs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Liver abnormalities</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>- Other abnormalities</td>
<td>aggressive beh</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MRI features:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- MTS</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- other abnormalities</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Legend: – Absent; + Present; beh-behavior; CB-congenital blindness; CC-cortical cysts; CMD-cortico-medullar differentiation; ELE-elevated liver enzymes; Hyd-hydrocephalus; LE-left eye; micropt-microptalmus; mo-months; MTS-molar tooth sign; n.a.-not applicable; NPH/UCD-Nephronophthisis / Urine Concentration Defect; ny-nystagmus; OMA-Oculomotor Apraxia; RP-retinitis pigmentosa; US-ultrasound; vr-visus reduction, yrs-years; ?-unknown